Effect of Astragalus and chemotherapy on the expression of VEGF in NSCLC, MVD and immune function
Objective To investigate the effect of Astragalus and chemotherapy on the expression of vascular endothelial growth factor(VEGF)in non-small cell lung cancer(NSCLC), microvessel density(MVD)and immune function.Methods 92 patients with NSCLC were divided into the study group and the control group, 46 cases in each group.Both groups were treated with neoadjuvant chemotherapy and operation, and the study group was treated with astragalus polysaccharide.The expression of VEGF in cancer tissues, MVD and immune function were compared between the two groups.The short-term and long-term curative effect and the incidence of adverse reactions were recorded.Results After treatment, positive rates of VEGF, MVD and blood CD8+ were significantly decreased in two groups (P<0.05), showing study group<control group (P<0.05), while blood CD3+, CD4+ and ratio of NK cells were significantly increased (P<0.05), showing study>control group (P<0.05).There were no significant differences between the two groups in short-term curative effect and 5 year survival rates.The incidence rates of side effects in the study group were significantly lower than those in the control group (P<0.05).Conclusion Adjuvant chemotherapy combined with intravenous infusion of Astragalus Polysaccharide can improve MVD, the expression of VEGF and immune function in patients with NSCLC.
astragaluschemotherapyNSCLCVEGFmicrovessel densityimmune function
NETL
NSTL
万方数据
维普
